Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer.
With docetaxel as effective chemotherapy for hormone refractory prostate cancer (HRPC), the number of new treatment combinations for HRPC is expanding demanding a fast-track screening system. This review elaborates on the use of xenograft models to select the most promising combination therapies for entering into phase II clinical trials.
van Weerden
W M
WM
Department of Urology, Josephine Nefkens Institute, Erasmus MC, Rotterdam, The Netherlands. w.vanweerden@erasmusmc.nl
Bangma
C
C
de Wit
R
R
D000726:Androgen Antagonists / Q000627:therapeutic use; D000818:Animals; D045744:Cell Line, Tumor; D017322:Clinical Trials, Phase II as Topic; D000077143:Docetaxel; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D043823:Taxoids / Q000627:therapeutic use; D023041:Xenograft Model Antitumor Assays / Q000379:methods*
D000726:Androgen Antagonists; D043823:Taxoids; D000077143:Docetaxel; D017430:Prostate-Specific Antigen